A Prospective, Two-arm, Non Interventional Study of JAKAVI (Ruxolitinib) in Patients With Myelofibrosis
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAKoMo
- Sponsors Novartis Pharmaceuticals
- 20 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Planned End Date changed from 30 Sep 2022 to 1 Oct 2022.
- 13 Sep 2022 Planned primary completion date changed from 30 Sep 2022 to 1 Oct 2022.